Workiva AI vs Komodo Health AI

Enterprise licensing. No public pricing. Annual contracts. Publicly traded (WK). Demo available.

Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.

Financial and ESG disclosure data processed on Workiva's infrastructure under enterprise data handling agreements with financial services security standards.

Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.

• ✓Most Fortune 500 public companies use Workiva — unmatched validation for financial and ESG reporting
• ✓AI consistency checking catches cross-reference errors that create SEC comment letters
• ✓ESG reporting framework alignment (GRI, SASB, TCFD, CSRD) covers major global sustainability disclosure requirements
• ✓Data connectivity eliminates manual data entry reducing error risk in filings

• ✓330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
• ✓Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
• ✓Pulse SaaS interface makes real-world evidence accessible without custom database development
• ✓Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data

• ✕Enterprise-only pricing — appropriate for public companies with formal reporting obligations
• ✕Implementation and adoption requires significant finance team change management
• ✕Not relevant for private companies without regulatory reporting obligations

• ✕Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
• ✕Real-world data has limitations — claims-based patient identification is less accurate than clinical data
• ✕Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials